9 news items
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA's Approval of a Telomerase Inhibitor Agent Therapy
MAIA
7 Jun 24
checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
MAIA
7 Jun 24
The phase 2 THIO-101 trial primarily focuses on assessing the safety and tolerability of THIO both
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
The primary objectives of the THIO-101 trial are to assess the safety and tolerability of THIO and its efficacy in terms of ORR. To date, THIO, combined
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA
6 Jun 24
and has an excellent safety profile, but 180mg has shown the greatest efficacy and is well tolerated compared to existing therapies. Hence, we selected
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
CORT
HALO
MAIA
6 Jun 24
Results in Third-Line Treatment
The THIO-101 trial, which focuses on the safety, tolerability
l533s 6gxgn9vfpuo69ut29gdec
MAIA
4 Jun 24
are to examine the safety and tolerability of THIO as an anticancer drug and as an immune system primer, and to examine the clinical efficacy of THIO
345vdnb 0o
AFMD
ALBT
BPTH
4 Jun 24
of the trial are to evaluate the safety and tolerability of THIO as both an anticancer compound and a priming immune activator, and to assess its clinical
1j2zt47pswdtj7uqg5rg
MAIA
22 May 24
.The clinical trial's positive results support THIO's tolerability and safety as an anticancer therapy and a priming immune activator. Treatment
74nj7t 09ogxnk1ajyvre34g1
MAIA
17 May 24
objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess
- Prev
- 1
- Next